Spyre Therapeutics Inc. Total Assets
Spyre Therapeutics Inc. total assets. Based on the latest financial reports, Spyre Therapeutics Inc. (SYRE) holds total assets worth $1.17 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Spyre Therapeutics Inc. worth for the company's overall valuation and market capitalisation.
Total Assets of Spyre Therapeutics Inc. (2013–2025)
Total assets of Spyre Therapeutics Inc. from 2013 to 2025. This chart illustrates how Spyre Therapeutics Inc.'s total assets have evolved over time, based on quarterly financial data. See Spyre Therapeutics Inc. (SYRE) share price today for real-time trading data and today's change.
Spyre Therapeutics Inc. - Asset Composition Analysis
Spyre Therapeutics Inc. Total Assets Breakdown (December 2025)
Spyre Therapeutics Inc. total assets breakdown as of December 2025. Spyre Therapeutics Inc.'s total assets of $1.17 Billion consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Spyre Therapeutics Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Spyre Therapeutics Inc. (SYRE) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Spyre Therapeutics Inc.'s current assets represent 100.0% of total assets in 2025, unchanged from 100.0% in 2013.
- Cash Position: Cash and equivalents constituted 11.0% of total assets in 2025, down from 100.0% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Spyre Therapeutics Inc. Competitors by Total Assets
Key competitors of Spyre Therapeutics Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Spyre Therapeutics Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 18.53 | 6.49 | 5.75 |
| Quick Ratio | 18.53 | 6.49 | 5.75 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.11 Billion | $455.77 Million | $97.09 Million |
Spyre Therapeutics Inc. - Advanced Valuation Insights
This section examines the relationship between Spyre Therapeutics Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.19 |
| Latest Market Cap to Assets Ratio | 10.12 |
| Asset Growth Rate (YoY) | 27.8% |
| Total Assets | $777.78 Million |
| Market Capitalization | $7.87 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Spyre Therapeutics Inc.'s assets at a significant premium (10.12x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Spyre Therapeutics Inc.'s assets grew by 27.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Spyre Therapeutics Inc. (2013–2025)
The table below shows the annual total assets of Spyre Therapeutics Inc. from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $777.78 Million | +27.82% |
| 2024-12-31 | $608.48 Million | +77.99% |
| 2023-12-31 | $341.86 Million | +380.52% |
| 2022-12-31 | $71.14 Million | -35.28% |
| 2021-12-31 | $109.93 Million | -31.98% |
| 2020-12-31 | $161.62 Million | +94.29% |
| 2019-12-31 | $83.18 Million | +7.00% |
| 2018-12-31 | $77.74 Million | +38.63% |
| 2017-12-31 | $56.08 Million | -16.38% |
| 2016-12-31 | $67.06 Million | +73.50% |
| 2015-12-31 | $38.65 Million | +1219.25% |
| 2014-12-31 | $2.93 Million | -36.26% |
| 2013-12-31 | $4.60 Million | -- |
About Spyre Therapeutics Inc.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative … Read more